Overview

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Status:
Active, not recruiting

Trial end date:
2022-01-04

Target enrollment:

Participant gender:

Summary

Study design This is a Phase II, open-label, multi-drug, multi-center, multi-arm, signal-searching study in patients with extensive-stage small-cell lung cancer (SCLC) who have refractory or resistant disease from prior platinum-based chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Adavosertib
Carboplatin
Durvalumab
Olaparib
Tremelimumab